Twist Bioscience Launches Multiplexed Gene Fragments to Enable High-throughput Screening Applications
13 Mai 2024 - 2:00PM
Business Wire
No limit to number of fragments included in the
pools
Optimized chemistry enables direct synthesis of
up to 500 bp double stranded fragments
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the launch of Twist
Multiplexed Gene Fragments (MGFs), pools of directly synthesized
double-stranded DNA (dsDNA) up to 500 base pairs in length with no
limit on sequence number to enable high throughput screening
applications.
“Using our chemical synthesis platform we are able to directly
synthesize Twist Multiplexed Gene Fragments as fragment pools of up
to 500 bp in length. By offering Twist's high-quality gene
fragments in a pooled format at prices that scale with the number
of sequences, Twist is enabling customers to conduct applications
that may have been previously unfeasible or cost-prohibitive,
facilitating high-throughput screening in a way that is far more
accessible to researchers across industry segments,” said Emily M.
Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “The
capability of pooling directly synthesized fragments with high
uniformity and representation allows for rapid screening of diverse
targets for CRISPR and genome engineering, facilitates entire
antibody variable coding regions for antibody discovery, and
supports long coding stretches of protein variants for protein
engineering applications.”
Twist MGFs are synthesized from customer-defined sequences up to
500 base pairs in length, generating an unlimited number of
high-quality DNA fragments in parallel. Twist MGFs encompass a
region large enough to span entire antibody variable domains and
UTRs, providing customers with a purpose-built product to meet
their needs. The expansive coding region also allows for customer
customization and multifaceted design options. The pooled format of
the fragments enables large-scale high-throughput screening.
Twist Multiplexed Gene Fragments (MGFs)
Twist Multiplexed Gene Fragments are pools of customizable
double-stranded DNA (dsDNA) between 301-500 base pairs in length.
Variant pool size starts at one thousand sequences, with no
maximum. Twist MGFs have a turnaround time starting at 8 business
days and can be easily integrated into a wide range of workflows
for applications including prime editing, ultra-complex
CRISPR-based functional screening, peptide and protein engineering,
antibody discovery, mRNA vaccine development and massively parallel
reporter assays (MPRA).
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on LinkedIn | X | YouTube | Instagram
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements regarding the
ability of Twist MGFs to enable customers to conduct applications
that may have been previously unfeasible or cost-prohibitive, and
make high-throughput screening more accessible to researchers
across industry segments. Forward-looking statements involve known
and unknown risks, uncertainties, and other important factors that
may cause Twist Bioscience’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the ability to achieve the expected benefits of Twist
Bioscience’s restructuring activities and reduced investments in
DNA data storage; the ability to attract new customers and retain
and grow sales from existing customers; the ability of Twist
Bioscience to achieve sufficient revenue to achieve or maintain
positive cash flow from operations or profitability in any given
period will depend heavily on the success of our existing products
and the development and commercialization of additional products in
the synthetic biology, biologic drug and data storage industries;
risks and uncertainties of rapidly changing technologies and
extensive competition in synthetic biology that could make the
products Twist Bioscience is developing obsolete or
non-competitive; uncertainties of the retention of significant
customers; the ability of Twist Bioscience to successfully
integrate acquired companies and to achieve expected benefits from
acquisitions; supply chain and other disruptions; risks of third
party claims alleging infringement of patents and proprietary
rights or seeking to invalidate Twist Bioscience’s patents or
proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies.
For a description of the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Annual Report on Form 10-K
filed with the SEC on November 21, 2023 and subsequent filings with
the SEC. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Twist Bioscience
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240513372494/en/
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Manager
774-265-5334 ahoulihan@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Twist Bioscience (NASDAQ:TWST)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024